SureTrader SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 9/5/2015 9:45:29 AM - Followers: 723 - Board type: Free - Posts Today: 4

 

(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit www.Amarantus.com, or connect with the company in FacebookTwitter, LinkedIn & Google+

 
 
    

 


 
PRESS RELEASES & NEWS ARTICLES
AUGUST 05, 2015
Amarantus Announces Adjournment of Annual Meeting  -  The annual meeting has been adjourned to August 7, 2015 at 10:00 a.m. EDT at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006
Aug. 3, 2015
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds - 
"This CRADA represents an important partnership for Amarantus as we work with the USAISR and Rutgers to advance the clinical program for ESS," said Gerald E. Commissiong, President & CEO of Amarantus.
AUGUST 03, 2015
Amarantus Diagnostics logo   Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 29, 2015
Amarantus BioScience Initiation of coverage Building up therapeutics assets
July 27, 2015
Amarantus Diagnostics Establishes Strategic Advisory Committee - Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
July 27, 2015 
SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34
JULY 24, 2015
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
July 22, 2015
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 20, 2015

More News
 
 
 

 Gerald E. Commissiong on LymPro 
Published on Jul 24, 2015

Predicting Alzheimer's before it starts
 Published on Apr. 8, 2015
                                                                                                                  
 

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014
 

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014

 

Amarantus BioScience
Oct. 19, 2014


 

 

 
    
       
 


Company Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111

 

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland












 

info@amarantus.com
pr@amarantus.com


Phone: (415) 688-4484
Fax: (408) 852-4427


Gerald's email address
Gerald@amarantus.com



IR Calendar 
 







 

INVESTOR RELATIONS

Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475

ir@amarantus.com


 

TRANSFER AGENT

VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com
www.VStockTransfer.com

 

 
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

 
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
 

                                                                                            
        
                           1 Conference

First MANF & CDNF Proteins Symposium - Two-Day International Symposium, San Francisco, CA  -  September 14 -15, 2015 

                                                             



 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 09/03/2015 07:46:26 AM
AMBS News: Amarantus Announces Results of Annual Meeting 09/03/2015 07:05:00 AM
AMBS News: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/26/2015 02:36:12 PM
AMBS News: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/26/2015 02:33:37 PM
AMBS News: Amarantus Moves Annual Meeting Date Forward to September 2, 2015 08/26/2015 12:30:00 PM
PostSubject
#116737  Sticky Note Jason Napodano, CFA ?@JNapodano 12h12 hours ago Rosym 08/04/15 08:53:08 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#117489   If I was a professional, and I knew joboggi 09/05/15 09:45:29 AM
#117488   Unfortunately, we have no idea what is going SidVicious 09/05/15 05:47:11 AM
#117487   Tell me why does GC keeps his mouth sante1 09/05/15 02:03:35 AM
#117486   I'm not able to figure out what is GS1 09/05/15 01:04:29 AM
#117485   I think news is coming on ESS, good mstrike 09/04/15 07:36:57 PM
#117484   Sept is qtr ending month so you will GS1 09/04/15 05:06:47 PM
#117483   AMBS's heroin style toxic death-spiral dilutive financing JPetroInc 09/04/15 04:18:42 PM
#117481   what a flippin series of fake communications and JPetroInc 09/04/15 03:18:51 PM
#117480   Posted on August 14th, 2013 JPetroInc 09/04/15 03:12:17 PM
#117479   OK time to paint the tape - with JPetroInc 09/04/15 03:06:11 PM
#117478   years and years of nothing der_deutschetrader 09/04/15 03:04:23 PM
#117477   Lol. Not good. I just wanted one PPP GOducks123 09/04/15 02:43:15 PM
#117475   we have significant potential for near term non-dilutive financing JPetroInc 09/04/15 02:29:10 PM
#117474   boy Gerald said we'd be "uplisting from strength" JPetroInc 09/04/15 02:21:07 PM
#117473   Looks like you might be right about testing GOducks123 09/04/15 02:17:07 PM
#117472   2.05 / 2.10 JPetroInc 09/04/15 02:11:31 PM
#117471   Dr. pepper. joboggi 09/04/15 01:46:16 PM
#117470   apologizes are in order JPetroInc 09/04/15 01:05:38 PM
#117469   If that's should be the case, it's very sante1 09/04/15 12:51:54 PM
#117468   Your timeframe is a bit off, they have brharris 09/04/15 12:27:12 PM
#117467   http://scr.zacks.com/files/September-2-2015_AMBS_Zeng.pdf It is $10 million for the Georgetown te joboggi 09/04/15 12:04:18 PM
#117466   absolutely "no one" can tell you anything with certainty JPetroInc 09/04/15 10:54:42 AM
#117465   Can anyone tell me? Dumbstockguy 09/04/15 10:47:00 AM
#117464   its $5-Mil. on the GT assay JPetroInc 09/04/15 10:22:04 AM
#117463   Well, first you have the run rate. That joboggi 09/04/15 10:12:59 AM
#117462   Real solid strength here. approx. 0.017 cents pre Shadowfaxin 09/04/15 09:56:43 AM
#117461   that's a great question for Mark Faerber or JPetroInc 09/04/15 09:48:01 AM
#117460   AMBS Down 93% YTD. Stay away from Sgt. Pepper 09/04/15 09:43:07 AM
#117459   Warning! 150-1 Reverse Split in play. Shares Sgt. Pepper 09/04/15 09:42:48 AM
#117458   TOXIC Financier DOMINION adds nearly 5% to ownership. Sgt. Pepper 09/04/15 09:42:37 AM
#117457   269% dilution approved IN THIS fraud Sgt. Pepper 09/04/15 09:42:23 AM
#117455   i don't short penny stocks der_deutschetrader 09/03/15 11:51:12 AM
#117454   May not want to get caught short here.... Didn't brharris 09/03/15 11:25:03 AM
#117453   why do you think they increased the a/s der_deutschetrader 09/03/15 11:15:45 AM
#117452   Sell target is $3.00 $AMBS LORD of the TITANS 09/03/15 11:07:58 AM
#117451   In for a flip, I won't hold this LORD of the TITANS 09/03/15 11:07:17 AM
#117450   Need to make previous resistance support. Glad to GOducks123 09/03/15 11:03:43 AM
#117449   Looking solid right now. Won't take much for brharris 09/03/15 11:02:07 AM
#117448   $2.50 printing L-2 JPetroInc 09/03/15 10:50:16 AM
#117447   Indeed. Nice to see some buying, let's see brharris 09/03/15 10:47:46 AM
#117446   Years or you mean weeks? Rotflmaoooooooooooooo LORD of the TITANS 09/03/15 10:35:07 AM
#117445   Got lots in the pipeline now. Time to GOducks123 09/03/15 10:21:20 AM
#117444   GC has already stated the company is NOT brharris 09/03/15 10:14:31 AM
#117443   The lower limit for uplist was $4. Then joboggi 09/03/15 10:00:11 AM
#117442   $$ AMBS $$ The only ones to know THE_BAMFACTSTER!! 09/03/15 09:49:01 AM
#117441   LOL! It was NEVER GOING TO UPLIST. :-d Sgt. Pepper 09/03/15 09:43:05 AM
#117440   If it falls to 1.50 how can it GreenMan 09/03/15 09:41:43 AM
#117439   $$ AMBS $$ WRONG sgt pepper !! THE_BAMFACTSTER!! 09/03/15 09:40:06 AM
#117438   I certainly hope that I am wrong, however Shadowfaxin 09/03/15 09:36:32 AM
#117437   AMBS Down 93% YTD. Stay away from Sgt. Pepper 09/03/15 09:34:18 AM
PostSubject